A Convenient Synthesis of 14C-Anthralin by Huang, H.S. et al.
1 4C-Anthralin 743 
A Convenient Synthesis of 14C-Anthralin 
Eine einfache Synthese für 14C-Anthralin 
Hsu-Shan Huang+), Klaus K. Mayer, Klaus Müller, and Wolfgang Wiegrebe 
Institut für Pharmazie, Pharmazeutische Chemie I, Universität Regensburg, D-93040 Regensburg, Germany 
Received July 4, 1994 
Anthralin [l,8-dihydroxy-9(10//)-anthracenone] is among the most 
widely used drugs in the topical treatment of psoriasis1). However, not 
much is known concerning its mode of action at the molecular level, 
although a variety of cellular targets have been implicated both in the main 
and side effects of anthralin 2 ). In particular, the interaction of anthralin 
with proteins has long been recognized to occur 3 , 4 ) and there has been 
renewed interest in this topic, mostly directed toward the investigation 
whether enzyme inhibition by anthralin is related to oxygen radical-
mediated damage of proteins 5 ). In order to gain a more profound 
understanding of the interaction between this drug and cellular targets, 
anthralin labelled with a non-exchangeable radioisotope in a suitable 
position was highly desirable. Furthermore, this labelled compound might 
serve as a useful starting material for the synthesis of analogues labelled in 
the anthrone nucleus. Since structural modification of anthralin has 
provided compounds with improved biological activity 6 ' 7), labelled 
compounds are required for studies on skin penetration and metabolism of 
these future drugs. 
Although routes to 1 4C-anthralin have already been described8 ,9), each of 
these methods suffers from too many synthetic steps, or the use of 
hazardous 1 4C-sources 1 ). In this paper, we describe a short and efficient 
synthesis of l,8-dihydroxy-[10-14C]-9(10//)-anthracenone. 
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Scheme 1: Synthesis of 1 4C-anthralin. Reagents: (a) C H 2 N 2 , ether; (b) 
L D A , THF; (c) 10% NaOH, 30% H 2 0 2 , ethanol; (d) SnCl 2 , H C l , glacial 
acetic acid. 
Chemistry 
Scheme 1 shows the pathway for the synthesis of 1 4 C -
anthralin, which is based on a procedure for the preparation 
+ ) On leave from the Institute of Pharmacy, National Defense Medical 
Center, Taipei, Taiwan, R.O.C. 
of anthracenediones described by Bhawal et al.n\ 
Accordingly, the commercially available 14C-source 
[2-14C]-cyanoacetic acid (1) was esterified with diazo-
methane to give the required methyl [2-14C]-cyanoacetate 
(2). Ester 2, upon reaction with the aryne obtained from 
3-bromoanisole and lithium diisopropylamide (LDA), gave 
[ 10- 1 4C] -10-cyano-9-hydroxy-1,8-dimethoxyanthracene (3) 
directly. - The mechanism of this reaction has been sug-
gested to consist of two pathways: a non-concerted [2 + 2] 
cycloaddition involving a tandem-addition rearrangement, 
and an aryne [4 + 2] cycloaddition1 [ ) . - Oxidation of 3 with 
hydrogen peroxide in alkaline solution11) gave [10-14C]-1,8-
dimethoxy-9,10-anthracenedione (4) in 80% yield. Final 
reduction of 4 with SnCl2 in acetic acid/hydrochloric acid 
proceeded with concomitant ether cleavage and cleanly 
produced [10-14C]-anthralin (5) in 86% yield. 
Experimental Part 
Melting points: Büchi 510 melting point apparatus, uncorrected.- EIMS: 
Varian M A T 311A (70 eV).- Analytical T L C : E M Science precoated T L C 
plates with silica gel F-254.- Tetrahydrofuran (THF) and diisopropylamine 
were distilled from L i A l H 4 and C a C l 2 , respectively. A l l other organic reac-
tants were distilled before use.- [2-14C]-cyanoacetic acid: American Radio-
labeled Chemicals Inc.- w-Butyllithium (rc-BuLi) and Diazald: Aldrich 
Chemical Co.- 3-Bromanisole: Fluka Chemie A G . - A l l reactions were car-
ried out in flame-dried flasks under N 2 . Radioactivity was measured using 
L S C (Liquid Scintillation Counter) "Quantums" 1220 ( L K B Wallac). 
Methyl [2-14C]-cyanoacetate (2) 
In a glove box (Atmos Bag, Aldrich) filled with N 2 , [2-14C]-cyanocetic 
acid (55 mCi/mmol ~ 23.9 GBq/g) was dissolved in absol. ether and mixed 
with unlabelled cyanoacetic acid (0.85 g, 10 mmol) in 10 ml of absol. 
ether. The solution was cooled in an ice bath and a distilled ethereal solu-
tion of diazomethane was added in small portions. After stirring for 1 h, 
the mixture was dried over N a 2 S 0 4 , distilled, and afforded 0.9 g (91%) of 
2, sufficiently pure for the next step. 
[10-14C]-10-Cyano-9-hydroxy-l ,8-dimethoxyanthracene (3) 
To a cooled (-78°C) solution of 2 (0.9 g, 9.1 mmol) in 10 ml of absol. 
THF, a cold solution of L D A (15 mmol in 30 ml in THF) was added over a 
period of 20 min, then the solution was stirred at -78°C for 15 min. Bro-
moanisole (3.8 g, 20 mmol) in 50 ml of absol. THF was added rapidly, the 
solution was warmed to -40°C, and a cooled (-40°C) solution of L D A (30 
mmol in 50 ml of absol. THF) was added slowly (ca. 30 min). The solution 
was stirred for an additional 10 min, then allowed to warm to room temp., 
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quenched with 20 ml of satd. NH 4 C1 solution, and the solvent was evapo-
rated in vacuo. The residue was dissolved in C H 2 C 1 2 (200 ml) and washed 
with dil. H C l (50 ml), then with a satd. aq. solution of NaCl , dried over 
N a 2 S 0 4 , and concentrated (rotary evaporator) to afford a sufficiently pure 
labelled substance, homogeneous by T L C (CH 2 C1 2 , Rf: 0.7). Yie ld 360 
mg, mp. 261°C [ l i t . n ) : 261-262°C].- A n experiment using a higher excess 
of aryne did not increase the incorporation rate of the label but triggered 
the formation of the pertinent trypticene derivative and non-identifed side 
products (tic). 
[10-MC]-1,8-Dimethoxy-9,10-anthracenedione (4) 
To a solution of 3 (360 mg, 1.3 mmol) in 50 ml of ethanol was added in 
one portion an aqueous solution containing 10% NaOH (10 ml) and 30% 
H 2 0 2 (10 ml). The mixture was stirred for 5 h at 75°C and then at room 
temp, for 12 h. The mixture was cooled to 0°C, the precipitated anthrace-
nedione was filtered, washed with water, and dried to give a pure product: 
280 mg (80%), mp. 223°C (li t . 1 2 ) : 223-224°C).- EIMS (70 eV): m/z 268 
(54), 253 (100), 251 (20), 152 (18), 139 (19). 
[10-14C]-l,8-Dihydroxy-9(10H)-anthracenone (5) 
To a refluxing solution of 4 (250 mg, 0.93 mmol) in glacial acetic acid 
(20 ml) a solution of 40% S n C l 2 in 37% H C l (5.0 ml) was added dropwise 
over 3 h. The solution was poured into 10 ml of ice water, and the 
resulting yellow precipitate was collected by filtration. Recrystallization 
from acetic acid afforded 5: 180 mg (86%), mp. 170°C (lit . 1 3 ) : 169-171°C). 
The activity cone, was determined using L S C "Quantums" by measuring 5 
(1.00 mg) dissolved in toluene (5 ml); the average activity cone, was 130 ± 
20 kBq/g.- EIMS (70 eV): m/z 227 (15), 226 (100), 225 (5), 198 (11), 197 
(13), 152 (9), 151 (8). 
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